IGC PHARMA, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-7.1M | $-13.0M | $-11.5M | $-15.0M | $-8.8M | $-7.3M | $-4.1M | $-1.8M |
| Depreciation & Amortization | $618.0K | $637.0K | $657.0K | $651.0K | $478.0K | $144.0K | $59.0K | $19.0K |
| Depreciation | $567.0K | $563.0K | $417.0K | $627.0K | $462.0K | $134.0K | $59.0K | — |
| Amortization | — | $74.0K | $57.0K | $24.0K | $16.0K | $10.0K | — | — |
| Stock-Based Compensation | $4.3M | $4.6M | $5.5M | $7.0M | $703.0K | $521.0K | $515.0K | $576.3K |
| Net Cash from Operating Activities | $-4.8M | $-5.2M | $-7.0M | $-7.5M | $-10.8M | $-8.7M | $-3.3M | $-1.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $112.0K | $138.0K | $310.0K | $236.0K | $1.5M | $4.4M | $15.0K | $136.0K |
| Business Acquisitions | — | — | — | — | — | — | $45.0K | $65.0K |
| Net Cash from Investing Activities | $-442.0K | $-317.0K | $-235.0K | $-742.0K | $3.4M | $-9.5M | $-260.0K | $-657.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $4.5M | $3.5M | $100.0K | $4.1M | $14.7M | $-59.0K | $27.6M | $3.7M |
| Net Change in Cash | $-793.0K | $-2.0M | $-7.3M | $-4.1M | $7.3M | $-18.4M | $24.0M | $1.1M |
| Free Cash Flow | $-4.9M | $-5.3M | $-7.4M | $-7.7M | $-12.3M | $-13.1M | $-3.3M | $-2.1M |